美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

OPUS GENETICS INC

3.50

-0.1400-3.85%

盤前：3.580.0800+2.29%08:40 EST

成交量：59.97萬

成交額：211.18萬

市值：2.41億

市盈率：-1.88

高：3.69

開：3.69

低：3.44

收：3.64

52周最高：3.97

52周最低：0.6500

股本：6,896.42萬

流通股本：6,312.22萬

量比：0.62

換手率：0.95%

股息：- -

股息率：- -

每股收益(TTM):-1.8600

每股收益(LYR):-2.1535

淨資產收益率：-338.75%

總資產收益率：-60.73%

市淨率：40.45

市盈率(LYR):-1.63

資料載入中...

總覽公司新聞資訊公告

Opus Genetics宣佈FDA受理0.75%酚妥拉明滴眼液補充新藥申請用於治療老花眼

BUZZ--美國股票走勢-Opus Genetics、MetaVia、Enbridge

BUZZ-Opus Genetics為視力項目孖展2,500萬美元后股價走高

Opus Genetics Inc孖展由Adage資本管理領投，Trails Edge資本合夥人與Marshall Wace跟投

Opus Genetics Inc預計2025年末模擬現金餘額7000萬美元，將支撐運營至2028年上半年

Opus Genetics, Inc.盤中異動下午盤股價大漲5.03%報3.55美元

Opus Genetics, Inc.盤中異動急速上漲5.21%

Opus Genetics, Inc.盤中異動股價大跌5.00%

Opus Genetics, Inc.盤中異動臨近收盤股價大漲5.18%

Opus Genetics獲得獨立數據監測委員會對Best病相1/2期臨床試驗的積極建議

BUZZ--美國股票走勢-Coinbase、百思買、Abercrombie & Fitch

BUZZ--美國股票走勢-Coinbase、百思買、Abercrombie & Fitch

BUZZ-派博桑德勒給予 Opus Genetics "增持 "評級

Opus Genetics開展Opgx-Best1期1/2基因治療臨床試驗，首位參與者已完成給藥

Opus Genetics, Inc.盤中異動早盤股價大跌5.08%報1.87美元

OPUS GENETICS INC：計劃申請FDA的新型罕見疾病證據原則（Rdep）審查流程

Opus Genetics公布OPGX-LCA5在5型Leber先天性黑矇症1/2期試驗中的積極兒科數據

Opus Genetics在關鍵性Lynx-3三期試驗中為首位患者給藥，評估0.75%酚妥拉明眼科溶液治療角膜屈光手術患者中間視覺低對比度條件下視覺障礙的療效

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IRD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":3.5,"timestamp":1772053200000,"preClose":3.64,"halted":0,"volume":599747,"hourTrading":{"tag":"盘前","latestPrice":3.58,"preClose":3.5,"latestTime":"08:40 EST","volume":48,"amount":169.17000000000002,"timestamp":1772113227808,"change":0.08,"changeRate":0.022857,"amplitude":0.031429},"delay":0,"changeRate":-0.03846153846153849,"floatShares":63122173,"shares":68964208,"eps":-1.86,"marketStatus":"盤前交易","change":-0.14,"latestTime":"02-26 08:47:14 EST","open":3.69,"high":3.69,"low":3.4399,"amount":2111816.7816117997,"amplitude":0.068709,"askPrice":3.6,"askSize":15,"bidPrice":3.48,"bidSize":874,"shortable":3,"etf":0,"ttmEps":-1.86,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":3.5,"preHourTrading":{"tag":"盘前","latestPrice":3.58,"preClose":3.5,"latestTime":"08:40 EST","volume":48,"amount":169.17000000000002,"timestamp":1772113227808,"change":0.08,"changeRate":0.022857,"amplitude":0.031429},"postHourTrading":{"tag":"盘后","latestPrice":3.5,"preClose":3.5,"latestTime":"19:54 EST","volume":2022,"amount":7077.62,"timestamp":1772067286344,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6224766304994439,"impliedVol":2.0358,"impliedVolPercentile":0.948},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":63122173,"roa":"-60.73%","roe":"-338.75%","lyrEps":-2.153504,"volumeRatio":0.6224766304994439,"shares":68964208,"dividePrice":0,"high":3.69,"amplitude":0.068709,"preClose":3.64,"low":3.4399,"week52Low":0.65,"pbRate":"40.45","psRate":"16.50","week52High":3.965,"institutionHeld":0,"latestPrice":3.5,"committee":0.966254,"eps":-1.86,"divideRate":0,"volume":599747,"delay":0,"ttmEps":-1.86,"open":3.69,"prevYearClose":2.01,"prevWeekClose":3.39,"prevMonthClose":2.31,"prevQuarterClose":2.01,"fiveDayClose":3.75,"twentyDayClose":2.83,"sixtyDayClose":2.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"盤前","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":12,"updateTime":1769317200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-02-25","current":-1.88172,"percent":0.006061,"low":-3.933416,"twenty":-2.153773,"median":-1.323479,"eighty":-1.038117,"high":-0.560128,"avg":-1.567001,"sd":0.679819,"marketCap":251029717},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-25","current":-3.680626,"twenty":-2.153773,"median":-1.323479,"eighty":-1.038117,"marketCap":251029717}],"updateTime":1772113634890},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1199651408","title":"Opus Genetics宣佈FDA受理0.75%酚妥拉明滴眼液補充新藥申請 用於治療老花眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1199651408","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199651408?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 19:59","pubTimestamp":1772020779,"startTime":"0","endTime":"0","summary":"Opus Genetics公司近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对0.75%酚妥拉明滴眼液所提交的补充新药申请（sNDA）。该药物旨在用于治疗老花眼，标志着公司在眼科治疗领域取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2611689051","title":"BUZZ--美國股票走勢-Opus Genetics、MetaVia、Enbridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2611689051","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611689051?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 22:12","pubTimestamp":1770991924,"startTime":"0","endTime":"0","summary":"nL4N3Z90X1 ** Expedia Group Inc EXPE.O:BUZZ - 在预测 2026 年调整后核心利润率增长放缓后下跌。nL4N3Z912F ** Wendy's Co WEN.O:BUZZ - 在年度利润预测低于预期后下跌。nL4N3Z9141 ** Watts Water Technologies Inc WTS.N:BUZZ - 因数据中心需求强劲，Stifel 上调 Watts Water 目标价。nL4N3Z911S ** Instacart Inc CART.O:BUZZ - 因第一季度预测和第四季度业绩乐观而跳涨。nL6N3Z90RQ ** Opus Genetics Inc IRD.O:BUZZ - 在为视力治疗项目融资 2500 万美元后上涨。nL4N3Z90ZC ** Bio-Rad Laboratories Inc BIO.N:BUZZ - 因第四季度利润不及预期而下滑。nL4N3Z9184 ** MetaVia Inc MTVA.O:BUZZ - 因肥胖症药物获得全球专利保护而上涨。nL4N3Z919F ** Enbridge Inc ENB.N:BUZZ - 季度利润超过预期，股价上涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL4T3Z91AT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HL","LU1035773651.USD","LU1169589451.USD","DKNG","CART","LU0345780281.USD","FDX","TOST","LU0154245756.USD","LU3187612489.SGD","EXPE","AU","BK4121","LU1104425308.USD","ABNB","LU0738911758.USD","WEN","LU1861558580.USD","RYAN","LU1015430645.USD","LU0456854461.SGD","LU2543165471.USD","IRD","TPH","WTS","RIVN","LU0345780950.USD","LU2317271919.USD","LU0266512127.USD","BK4539","NEM","CDE","ENB","ROKU","CHRS","LU0788109121.HKD","LU0345780521.USD","LU2237443978.SGD","MTVA","PINS","BK4608","PRU.UK","DLTR","AAP","IMUX","HK0000914660.USD","HWM","BK4114","BIO","AMKR"],"gpt_icon":0},{"id":"2611157970","title":"BUZZ-Opus Genetics為視力項目孖展2,500萬美元后股價走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611157970","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611157970?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 21:20","pubTimestamp":1770988838,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL4S3Z917L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"1134293259","title":"Opus Genetics Inc孖展由Adage資本管理領投，Trails Edge資本合夥人與Marshall Wace跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1134293259","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134293259?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:33","pubTimestamp":1770985994,"startTime":"0","endTime":"0","summary":"生物技术公司Opus Genetics Inc宣布完成新一轮融资。本轮融资由知名投资机构Adage资本管理担任领投方，同时吸引了Trails Edge资本合伙人与Marshall Wace等投资机构参与跟投。\n此次融资将主要用于推进公司基因治疗管线的临床开发，并加强其核心技术平台的优化升级。市场分析认为，多家专业投资机构的共同参与，显示出资本市场对Opus Genetics Inc技术实力与发展前景的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"1194250843","title":"Opus Genetics Inc預計2025年末模擬現金餘額7000萬美元，將支撐運營至2028年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1194250843","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194250843?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:31","pubTimestamp":1770985904,"startTime":"0","endTime":"0","summary":"生物技术公司Opus Genetics Inc近日公布财务预测，预计到2025年末公司模拟现金余额将达到7000万美元。这一资金规模预计足以支持其核心研发与商业运营持续进行至2028年上半年，为基因治疗管线的长期发展提供稳定财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2610672826","title":"Opus Genetics, Inc.盤中異動 下午盤股價大漲5.03%報3.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672826","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610672826?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 04:11","pubTimestamp":1770754308,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日04时11分，Opus Genetics, Inc.股票出现异动，股价大幅拉升5.03%。Opus Genetics, Inc.股票所在的生物技术行业中，整体跌幅为0.49%。Opus Genetics, Inc.公司简介：Opus Genetics Inc是一家临床阶段的眼科生物制药公司，开发治疗遗传性视网膜疾病患者的疗法，以及治疗其他视网膜和屈光性疾病患者的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211041148a494ca59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211041148a494ca59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LCA","BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2609231598","title":"Opus Genetics, Inc.盤中異動 急速上漲5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609231598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609231598?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 00:28","pubTimestamp":1770308922,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日00时28分，Opus Genetics, Inc.股票出现异动，股价快速拉升5.21%。Opus Genetics, Inc.股票所在的生物技术行业中，整体跌幅为0.71%。Opus Genetics, Inc.公司简介：Opus Genetics Inc是一家临床阶段的眼科生物制药公司，开发治疗遗传性视网膜疾病患者的疗法，以及治疗其他视网膜和屈光性疾病患者的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020600284297a512a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020600284297a512a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IRD","BK4139","BK4007","LCA"],"gpt_icon":0},{"id":"2609305774","title":"Opus Genetics, Inc.盤中異動 股價大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609305774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609305774?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 23:55","pubTimestamp":1770220528,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日23时55分，Opus Genetics, Inc.股票出现异动，股价急速下挫5.00%。Opus Genetics, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Opus Genetics, Inc.公司简介：Opus Genetics Inc是一家临床阶段的眼科生物制药公司，开发治疗遗传性视网膜疾病患者的疗法，以及治疗其他视网膜和屈光性疾病患者的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204235529953fd83a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204235529953fd83a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","IRD","LCA"],"gpt_icon":0},{"id":"2603633716","title":"Opus Genetics, Inc.盤中異動 臨近收盤股價大漲5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603633716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603633716?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 04:31","pubTimestamp":1768249879,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日04时31分，Opus Genetics, Inc.股票出现波动，股价快速上涨5.18%。Opus Genetics, Inc.股票所在的生物技术行业中，整体跌幅为1.21%。Opus Genetics, Inc.公司简介：Opus Genetics Inc是一家临床阶段的眼科生物制药公司，开发治疗遗传性视网膜疾病患者的疗法，以及治疗其他视网膜和屈光性疾病患者的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113043119953c7534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113043119953c7534&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LCA","IRD"],"gpt_icon":0},{"id":"1119412428","title":"Opus Genetics獲得獨立數據監測委員會對Best病相1/2期臨床試驗的積極建議","url":"https://stock-news.laohu8.com/highlight/detail?id=1119412428","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119412428?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 20:06","pubTimestamp":1765282015,"startTime":"0","endTime":"0","summary":"Opus Genetics获得独立数据监测委员会对Best病相1/2期临床试验的积极建议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2586507479","title":"BUZZ--美國股票走勢-Coinbase、百思買、Abercrombie & Fitch","url":"https://stock-news.laohu8.com/highlight/detail?id=2586507479","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586507479?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080173,"startTime":"0","endTime":"0","summary":"nL6N3X10P9 ** Zeta Global Holdings Corp ZETA.N：BUZZ - 在上调季度和年度预测后上涨   nL4N3X10Q2 ** Vistra Corp VST.N：BUZZ--KeyBanc给予Vistra \"增持 \"评级。nL6N3X10S3 ** PTC Therapeutics PTCT.O：BUZZ - 该公司将加入标准普尔小型股指数，有望再创新高   nL6N3X10RH ** Firefly Aerospace Inc FLY.O：BUZZ - 因推迟上市，摩根大通下调Firefly Aerospace的PT值   nL6N3X10SL ** Lixte Biotechnology Holdings Inc LIXT.O：BUZZ - 收购英国公司，进军质子治疗癌症领域，股价上涨   nL4N3X10WN ** Keysight Technologies Inc KEYS.N：BUZZ - 因乐观的第一季度预测而跳涨；券商上调了预测价值   nL4N3X10TP (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4T3X10Z1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNC","TITN","ADI","LU1301847155.USD","IRD","CDE","89988","ABCB","BK1610","LU0708995401.HKD","PTCT","ESPR","HBBD.SI","LU2237443978.SGD","LU0531971595.HKD","FLY","HL","LU0994945656.USD","UPWK","FIBK","ALBmain","BBY","LIXT","LU2360107325.USD","ZM","COIN","ZETA","APD","LU0943347566.SGD","VST","SYM","KEYS","ATAT","SPOT","LU2491049909.HKD","IE00BFMHRM44.USD","DD","EXOD","LU0496367417.USD","LU0689472784.USD","ANF","AU"],"gpt_icon":1},{"id":"2586479501","title":"BUZZ--美國股票走勢-Coinbase、百思買、Abercrombie & Fitch","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479501","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479501?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080173,"startTime":"0","endTime":"0","summary":"nL6N3X10P9 ** Zeta Global Holdings Corp ZETA.N：BUZZ - 在上调季度和年度预测后上涨   nL4N3X10Q2 ** Vistra Corp VST.N：BUZZ--KeyBanc给予Vistra \"增持 \"评级。nL6N3X10S3 ** PTC Therapeutics PTCT.O：BUZZ - 该公司将加入标准普尔小型股指数，有望再创新高   nL6N3X10RH ** Firefly Aerospace Inc FLY.O：BUZZ - 因推迟上市，摩根大通下调Firefly Aerospace的PT值   nL6N3X10SL ** Lixte Biotechnology Holdings Inc LIXT.O：BUZZ - 收购英国公司，进军质子治疗癌症领域，股价上涨   nL4N3X10WN ** Keysight Technologies Inc KEYS.N：BUZZ - 因乐观的第一季度预测而跳涨；券商上调了预测价值   nL4N3X10TP (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4S3X10Z1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0700851271.USD","COIN","APD","FLNC","FLY","ADI","TITN","ANF","PTCT","BK4101","FIBK","SYM","SPOT","UPWK","LU1211504680.USD","AU","ABCB","ESPR","BBY","DD","IE00B543WZ88.USD","ATAT","ZETA","VST","LU0128525929.USD","HL","LU0348783662.USD","SG9999015945.SGD","LU0543330483.HKD","LU1003077747.HKD","ZM","CDE","89988","HBBD.SI","LU0070302665.USD","LU0289960550.SGD","EXOD","LIXT","KEYS","ALBmain","IRD","SG9999001093.SGD"],"gpt_icon":1},{"id":"2586420356","title":"BUZZ-派博桑德勒給予 Opus Genetics \"增持 \"評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420356","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420356?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 20:03","pubTimestamp":1764072216,"startTime":"0","endTime":"0","summary":"BUZZ-派博桑德勒给予 Opus Genetics \"增持 \"评级11月25日 - ** Piper Sandler启动了对Opus Genetics IRD.O的覆盖，给予 \"增持 \"评级；将目标价定为7美元，与该股上次收盘价相比有约250%的上涨空间** 处于临床阶段的生物制药公司股价盘前上涨 4.5% 至 2.09 美元 ** IRD的主导项目OPGx-LCA5在一种超罕见眼病(LCA5的早期临床数据强劲，券商因此看好IRD。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4S3X10QZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"1159635757","title":"Opus Genetics開展Opgx-Best1期1/2基因治療臨床試驗，首位參與者已完成給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1159635757","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159635757?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 20:01","pubTimestamp":1763035272,"startTime":"0","endTime":"0","summary":"Opus Genetics开展Opgx-Best1期1/2基因治疗临床试验，首位参与者已完成给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2582341941","title":"Opus Genetics, Inc.盤中異動 早盤股價大跌5.08%報1.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582341941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582341941?lang=zh_tw&edition=fundamental","pubTime":"2025-11-11 23:33","pubTimestamp":1762875222,"startTime":"0","endTime":"0","summary":"北京时间2025年11月11日23时33分，Opus Genetics, Inc.股票出现异动，股价急速下挫5.08%。Opus Genetics, Inc.股票所在的生物技术行业中，整体涨幅为0.62%。Opus Genetics, Inc.公司简介：Opus Genetics Inc是一家临床阶段的眼科生物制药公司，开发治疗遗传性视网膜疾病患者的疗法，以及治疗其他视网膜和屈光性疾病患者的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111233342a6f254df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111233342a6f254df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LCA","BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"1182430757","title":"OPUS GENETICS INC：計劃申請FDA的新型罕見疾病證據原則（Rdep）審查流程","url":"https://stock-news.laohu8.com/highlight/detail?id=1182430757","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182430757?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 20:12","pubTimestamp":1762431137,"startTime":"0","endTime":"0","summary":"OPUS GENETICS INC：计划申请FDA的新型罕见疾病证据原则（Rdep）审查流程","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"1153491222","title":"Opus Genetics公布OPGX-LCA5在5型Leber先天性黑矇症1/2期試驗中的積極兒科數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1153491222","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153491222?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 19:04","pubTimestamp":1759230270,"startTime":"0","endTime":"0","summary":"Opus Genetics公布了其OPGX-LCA5药物在治疗5型Leber先天性黑矇症（LCA5）的1/2期临床试验中获得的积极儿科患者数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"1194408460","title":"Opus Genetics在關鍵性Lynx-3三期試驗中為首位患者給藥，評估0.75%酚妥拉明眼科溶液治療角膜屈光手術患者中間視覺低對比度條件下視覺障礙的療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1194408460","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194408460?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 20:05","pubTimestamp":1756987523,"startTime":"0","endTime":"0","summary":"Opus Genetics公司宣布，在其关键性Lynx-3三期临床试验中成功为第一位患者给药。该试验旨在评估0.75%酚妥拉明眼科溶液在治疗角膜屈光手术患者中间视觉、低对比度条件下视觉障碍方面的有效性和安全性。\n这项重要的三期临床试验标志着该公司在眼科治疗领域取得的重要进展，为那些在中间光照和低对比度环境下出现视觉困扰的角膜屈光手术患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}